KR20230086819A - Composition for disinfection - Google Patents
Composition for disinfection Download PDFInfo
- Publication number
- KR20230086819A KR20230086819A KR1020237019184A KR20237019184A KR20230086819A KR 20230086819 A KR20230086819 A KR 20230086819A KR 1020237019184 A KR1020237019184 A KR 1020237019184A KR 20237019184 A KR20237019184 A KR 20237019184A KR 20230086819 A KR20230086819 A KR 20230086819A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- chondroitin sulfate
- oil
- disinfection
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 238000004659 sterilization and disinfection Methods 0.000 title abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000000645 desinfectant Substances 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract description 31
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract description 31
- 229940059329 chondroitin sulfate Drugs 0.000 abstract description 31
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 18
- 241000894006 Bacteria Species 0.000 abstract description 15
- 239000004094 surface-active agent Substances 0.000 abstract description 15
- 238000002156 mixing Methods 0.000 abstract description 14
- 239000002562 thickening agent Substances 0.000 abstract description 13
- 229920002567 Chondroitin Polymers 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 10
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 abstract description 10
- 230000001954 sterilising effect Effects 0.000 abstract description 9
- 230000000249 desinfective effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 25
- -1 fatty acid ester Chemical class 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 15
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 229920002125 Sokalan® Polymers 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002736 nonionic surfactant Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 4
- 229960001950 benzethonium chloride Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- 229960005443 chloroxylenol Drugs 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000010671 sandalwood oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
본 발명은 손가락 등의 살균 등에 사용하는 소독제에 속하는 것으로, 보습제로서 콘드로이틴황산 또는 콘드로이틴황산염을 배합함으로써, 보습성을 향상시키고, 세균이나 바이러스의 침입 및 감염의 원인이 되는 손의 거칠음을 방지하면서, 콘드로이틴황산 또는 콘드로이틴황산염을 조성물 중에 균일하게 존재시키는 소독용 조성물을 제공하는 것을 목적으로 하는 것으로, 탄소수 1∼3의 저급 알코올을 20∼60중량%, 물을 40∼65중량%, 콘드로이틴황산 또는 콘드로이틴황산염을 0.006∼1중량% 함유하는, 소독용 조성물 및 유지 성분, 증점제 및 계면활성제를 함유하고, 25℃에서의 점도가 50∼300Pa·s인, 소독용 조성물 등에 의해 해결할 수 있는 것이다.The present invention belongs to a disinfectant used for sterilization of fingers, etc., by blending chondroitin sulfate or chondroitin sulfate as a moisturizing agent, improving moisturizing properties, preventing roughness of hands that cause invasion and infection of bacteria or viruses, An object of the present invention is to provide a composition for disinfection in which chondroitin sulfate or chondroitin sulfate is uniformly present in the composition, wherein 20 to 60% by weight of lower alcohol having 1 to 3 carbon atoms, 40 to 65% by weight of water, chondroitin sulfate or chondroitin It can be solved by a disinfecting composition containing 0.006 to 1% by weight of sulfate and a disinfecting composition containing an oil and fat component, a thickener and a surfactant, and having a viscosity of 50 to 300 Pa·s at 25°C.
Description
본 발명은 손가락 등의 살균 등에 사용하는 소독제에 속하는 것으로, 보습성 및 성상이 우수한 소독용 조성물에 관한 것이다.The present invention belongs to a disinfectant used for sterilization of fingers and the like, and relates to a disinfectant composition having excellent moisturizing properties and properties.
종래, 에탄올, 이소프로필알코올 등 탄소수 1∼3의 저급 알코올이 세균의 세포막이나 바이러스의 엔벨로프의 파괴나 효소 등의 단백질의 응고에 의해 세균이나 바이러스에 대해 소독 작용을 갖는 것은 일반적으로 알려져 있고, 상기 저급 알코올을 배합한 소독제는 널리 사용되고 있다. 그러나, 일반적으로 에탄올, 이소프로필알코올 등의 저급 알코올을 배합한 소독제에서는 예를 들면, 손가락을 소독하기 위해 사용함에 있어서, 사용자의 손의 거칠음 등을 일으키는 문제가 있다. 손의 거칠음은 각층(角層)과 피지막이 제거되고 각층이 떨어져, 피부 배리어 기능이 상실된 상태를 가리키고, 이 상태는 배리어 결손부로부터 세균이나 바이러스가 침입함으로써 감염되기 쉬워지고 있다고 할 수 있다. 이러한 점에서, 저급 알코올을 배합해도 손의 거칠음, 즉 피부 배리어 기능의 결손을 방지할 수 있는 보습성이 우수한 소독제가 요망되고 있다.Conventionally, it is generally known that lower alcohols having 1 to 3 carbon atoms, such as ethanol and isopropyl alcohol, have a disinfecting action against bacteria and viruses by destroying bacterial cell membranes or viral envelopes or coagulating proteins such as enzymes. Disinfectants formulated with lower alcohol are widely used. However, in general, in disinfectants containing lower alcohol such as ethanol and isopropyl alcohol, when used to disinfect fingers, for example, there is a problem of causing roughness of the user's hands. The roughness of the hands refers to a state in which the stratum corneum and the sebaceous film are removed and the stratum corneum falls off, and the skin barrier function is lost. From this point of view, there is a demand for an antiseptic having excellent moisturizing properties that can prevent roughness of hands, that is, loss of skin barrier function, even when a lower alcohol is incorporated.
예를 들면, 특허문헌 1에는 카르복시비닐폴리머, 천연 다당류 등 지방산에스테르 및 저급 알코올을 함유하고, 그 저급 알코올의 배합 비율이 20∼50중량%인 소독제가 개시되어 있다. 점성제인 카르복시비닐폴리머를 배합함으로써, 손가락에 문질렀을 때에 손가락의 염류에 의해 폴리머 성분이 손가락 위에 석출(수지화)되는, 이른바 뭉침이 발생되기 때문에, 이를 방지하기 위해 천연 다당류나 그 유도체를 배합하고 있는 것을 특징으로 하고 있다.For example, Patent Document 1 discloses a disinfectant containing a carboxyvinyl polymer, a fatty acid ester such as a natural polysaccharide, and a lower alcohol, and the blending ratio of the lower alcohol is 20 to 50% by weight. By blending carboxyvinyl polymer, which is a viscous agent, so-called clumping occurs in which the polymer component precipitates (resinizes) on the finger due to the salts of the finger when rubbed on the finger. To prevent this, natural polysaccharide or a derivative thereof is blended It is characterized by having
그러나, 특허문헌 1의 실시예에 기재되어 있는 조성물에서는 보습성이 충분하지 않다는 과제가 존재하였다.However, in the composition described in the examples of Patent Document 1, there was a problem that moisturizing properties were not sufficient.
또한, 특허문헌 1에 기재된 발명에서는 천연 다당류로서 콘드로이틴황산나트륨을 사용하는 것이 시사되어 있지만, 실제로 콘드로이틴황산나트륨을 배합하면, 조성물의 다른 성분의 밸런스에 의해 용해되지 않는 등 조성물 중에 균일하게 존재시킬 수 없다는 문제가 있었다.Further, in the invention described in Patent Document 1, it is proposed to use sodium chondroitin sulfate as a natural polysaccharide, but when chondroitin sodium sulfate is actually blended, the problem is that it cannot be uniformly present in the composition, such as not dissolving due to the balance of other components in the composition. there was
그래서, 본 발명에서는 손가락 등의 살균 등에 사용하는 소독제에 속하는 것으로, 보습제로서 콘드로이틴황산 또는 콘드로이틴황산염을 배합함으로써 보습성을 향상시키고, 세균이나 바이러스의 침입 및 감염의 원인이 되는 손의 거칠음을 방지하면서, 콘드로이틴황산 또는 콘드로이틴황산염을 조성물 중에 균일하게 존재시키는 소독용 조성물을 제공하는 것을 목적으로 한다.Therefore, in the present invention, it belongs to a disinfectant used for sterilization of fingers, etc., and by blending chondroitin sulfate or chondroitin sulfate as a moisturizing agent, the moisturizing property is improved, and roughness of the hand, which is the cause of invasion and infection of bacteria or viruses, is prevented. It is an object of the present invention to provide a disinfectant composition in which chondroitin sulfate or chondroitin sulfate is uniformly present in the composition.
[1] 즉, 본 발명은 탄소수 1∼3의 저급 알코올을 20∼60중량%, 물을 40∼65중량%, 콘드로이틴황산 또는 콘드로이틴황산염을 0.006∼1중량% 함유하는 것을 특징으로 하는 소독용 조성물이다.[1] That is, the present invention is a disinfectant composition characterized in that it contains 20 to 60% by weight of lower alcohol having 1 to 3 carbon atoms, 40 to 65% by weight of water, and 0.006 to 1% by weight of chondroitin sulfate or chondroitin sulfate. am.
[2] 그리고, 유지 성분, 증점제 및 계면활성제를 함유하고, 25℃에서의 점도가 50∼300Pa·s인 것을 특징으로 하는 상기 [1]에 기재된 소독용 조성물이다.[2] The composition for disinfection according to [1] above, which contains an oil and fat component, a thickener, and a surfactant, and has a viscosity of 50 to 300 Pa·s at 25°C.
[3] 그리고, 상기 증점제가 카르복시비닐폴리머, 셀룰로오스 유도체로부터 선택되는 적어도 하나인 것을 특징으로 하는 상기 [1] 또는 상기 [2]에 기재된 소독용 조성물이다.[3] The disinfectant composition according to [1] or [2] above, wherein the thickener is at least one selected from carboxyvinyl polymer and cellulose derivative.
[4] 그리고, 상기 계면활성제가 폴리옥시에틸렌알킬에테르 및 다가 알코올의 지방산에스테르를 함유하는 것을 특징으로 하는 상기 [1] 또는 상기 [2]에 기재된 소독용 조성물이다.[4] The disinfectant composition according to [1] or [2] above, wherein the surfactant contains a polyoxyethylene alkyl ether and a fatty acid ester of a polyhydric alcohol.
[5] 그리고, 벤제토늄염화물, 염화벤잘코늄, 글루콘산클로르헥시딘, 포비돈요오드, 이소프로필메틸페놀, 클로록실레놀로부터 선택되는 적어도 하나의 소독 성분을 함유하는 것을 특징으로 하는 상기 [1] 또는 상기 [2]에 기재된 소독용 조성물이다.[5] In addition, the above [1] or the above characterized in that it contains at least one disinfectant component selected from benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate, povidone iodine, isopropylmethylphenol, and chloroxylenol. It is the composition for disinfection described in [2].
본 발명에 의하면, 손가락 등의 살균 등에 사용하는 살균제에 속하는 것으로, 보습제로서 콘드로이틴황산 또는 콘드로이틴황산염을 배합함으로써, 보습성을 향상시키고, 세균이나 바이러스의 침입 및 감염의 원인이 되는 손의 거칠음을 방지하면서, 콘드로이틴황산 또는 콘드로이틴황산염을 조성물 중에 균일하게 존재시킬 수 있다.According to the present invention, it belongs to a disinfectant used for sterilization of fingers, etc., and by blending chondroitin sulfate or chondroitin sulfate as a moisturizing agent, the moisturizing property is improved, and roughness of the hand that causes invasion and infection of bacteria or viruses is prevented. While doing so, chondroitin sulfate or chondroitin sulfate may be uniformly present in the composition.
이하, 본 발명의 소독용 조성물에 관한 실시형태에 대해 상세하게 설명한다. 또한, 설명 중에서의 범위를 나타내는 표기가 있는 경우는 상한과 하한을 함유하는 것이다.Hereinafter, embodiments relating to the composition for disinfection of the present invention will be described in detail. In addition, when there is a notation indicating a range in the description, the upper limit and the lower limit are included.
본 발명에서의 탄소수 1∼3의 저급 알코올은 메탄올, 에탄올, 이소프로필알코올 등의 탄소수가 1개 내지 3개의 알코올이다. 상기 저급 알코올을 사용함으로써, 세균의 세포막이나 바이러스의 엔벨로프의 파괴나 효소 등의 단백질의 응고에 의해 세균이나 바이러스를 사멸시켜, 상기 세균이나 바이러스에 의한 질병 등 인체에 대한 악영향을 예방할 수 있다.The lower alcohol having 1 to 3 carbon atoms in the present invention is an alcohol having 1 to 3 carbon atoms such as methanol, ethanol and isopropyl alcohol. By using the lower alcohol, bacteria or viruses are killed by destruction of cell membranes of bacteria or envelopes of viruses or coagulation of proteins such as enzymes, and adverse effects on the human body, such as diseases caused by the bacteria or viruses, can be prevented.
탄소수 1∼3의 저급 알코올의 소독용 조성물에서의 함유 비율로는 20∼60중량%인 것이 바람직하다. 그 함유 비율이 60중량%를 초과하면 콘드로이틴황산 또는 콘드로이틴황산염이 균일하게 용해 또는 분산될 수 없다. 또한, 그 함유 비율이 20중량% 미만이면 세균이나 바이러스를 충분히 소독할 수 없어, 원하는 효과를 발현하기 위해 다른 살균 성분 등을 첨가할 필요가 있다.It is preferable that it is 20 to 60 weight% as a content rate in the composition for disinfection of a C1-C3 lower alcohol. When the content ratio exceeds 60% by weight, chondroitin sulfate or chondroitin sulfate cannot be uniformly dissolved or dispersed. In addition, if the content ratio is less than 20% by weight, bacteria and viruses cannot be sufficiently disinfected, and other bactericidal components and the like must be added in order to express the desired effect.
본 발명에서의 콘드로이틴황산 또는 콘드로이틴황산염은 D-글루콘산 및 N-아세틸-D-갈락토사민으로 이루어지는 2당을 구성 단위로 하는 당사슬에 황산이 결합된 화합물 또는 그 황산의 수소가 나트륨, 칼륨 등으로 치환된 염이고, 보습제로서 배합된다. 콘드로이틴황산 또는 콘드로이틴황산염을 배합함으로써, 소독용 조성물에서의 보습성, 특히 시간이 경과했을 때에서의 보습성이 양호해진다.Chondroitin sulfate or chondroitin sulfate in the present invention is a compound in which sulfuric acid is bound to a sugar chain having a disaccharide composed of D-gluconic acid and N-acetyl-D-galactosamine as a constituent unit, or hydrogen of the sulfuric acid is sodium, potassium, etc. It is a salt substituted with and is formulated as a moisturizing agent. By blending chondroitin sulfate or chondroitin sulfate, the moisturizing properties of the composition for disinfection, particularly the moisturizing properties over time, are improved.
콘드로이틴황산 또는 콘드로이틴황산염의 소독용 조성물에서의 함유 비율로는 0.006∼1중량%인 것이 바람직하다. 그 함유 비율이 상기 범위이면, 소독용 조성물에서 균일하게 용해 또는 분산될 수 있고, 또한, 보습성이 계속되어 사용자의 손의 거칠음 등을 방지할 수 있다.The content of chondroitin sulfate or chondroitin sulfate in the composition for disinfection is preferably 0.006 to 1% by weight. When the content ratio is within the above range, it can be uniformly dissolved or dispersed in the disinfectant composition, and also, the moisturizing properties are continued to prevent roughness of the user's hands.
본 발명에서의 유지분은 20℃∼25℃의 상온에서 액체 또는 고형의 유지이다. 필요에 따라 배합할 수 있다. 유지분을 유화함으로써, 소독용 조성물을 사용했을 때, 그 유지분이 손가락 등의 피부에 퍼져 피부로부터 수분이 휘발되는 것을 억제함으로써 손의 거칠음 등을 방지할 수 있다. 유지분으로는 천연물, 합성물 전부 사용할 수 있고, 천연물로서 식물 유래, 동물 유래 중 어느 유지도 사용할 수 있다.The fats and oils in the present invention are liquid or solid fats and oils at room temperature of 20°C to 25°C. Can be mixed as needed. By emulsifying the fats and oils, when the composition for disinfection is used, the oils and fats spread on the skin of the fingers and the like to prevent volatilization of moisture from the skin, thereby preventing roughness of the hands. Both natural and synthetic oils and fats can be used, and either plant-derived or animal-derived oils can be used as natural products.
유지분으로는 예를 들면, 유동 파라핀, 경질 유동 파라핀, 스쿠알란 등의 탄화수소, 팔미트산이소프로필, 팔미트산옥틸, 미리스트산이소프로필, 이소노난산이소노닐, 탄소수 8∼탄소수 22의 지방산으로 이루어지는 중쇄 지방산트리글리세리드, 트리(카프릴·카프르산)글리세릴 등의 에스테르유, 미리스틸알코올(탄소수 14), 세타놀(탄소수 16), 스테아릴알코올(탄소수 18), 세토스테아릴알코올(탄소수 16 및 18의 혼합물), 베헤닐알코올(탄소수 22), 이소스테아릴알코올(탄소수 18), 2-헥실데카놀(탄소수 16), 2-옥틸도데카놀(탄소수 20) 등의 포화 1가 알코올류나, 올레일알코올(탄소수 18) 등의 불포화 1가 알코올 등의 지방족 알코올, 대두유, 사플라워유, 포도씨유, 로즈힙유, 해바라기유, 달맞이꽃종자유, 면실유, 참기름, 소맥배아유, 아몬드유 등이 바람직하고, 불건성유로는 올리브유, 산다화유, 동백유, 피마자유, 땅콩유, 아보카도유, 마카다미아너트유, 헤이즐너트유, 메도우폼유, 호호바유 등이 바람직하고, 정유로는 유칼립투스유, 박하유, 로만카모마일유 등(식물유)이 바람직하다. 상기 유지분은 1종만 또는 2종 이상 조합하여 사용할 수 있다.Examples of the fats and oils include hydrocarbons such as liquid paraffin, light liquid paraffin, and squalane, isopropyl palmitate, octyl palmitate, isopropyl myristate, isononanoate, and carbon atoms of 8 to 22 carbon atoms. Medium-chain fatty acid triglycerides composed of fatty acids, ester oils such as tri(caprylic capric acid) glyceryl, myristyl alcohol (carbon number 14), cetanol (carbon number 16), stearyl alcohol (carbon number 18), cetostearyl alcohol (a mixture of 16 and 18 carbon atoms), behenyl alcohol (22 carbon atoms), isostearyl alcohol (18 carbon atoms), 2-hexyldecanol (16 carbon atoms), 2-octyldodecanol (20 carbon atoms), etc. Alcohols, aliphatic alcohols such as unsaturated monohydric alcohols such as oleyl alcohol (carbon number 18), soybean oil, safflower oil, grapeseed oil, rosehip oil, sunflower oil, evening primrose oil, cottonseed oil, sesame oil, wheat germ oil, almond oil and the like are preferred, and non-drying oils include olive oil, sandalwood oil, camellia oil, castor oil, peanut oil, avocado oil, macadamia nut oil, hazelnut oil, meadow foam oil, jojoba oil, and the like, and essential oils include eucalyptus oil and peppermint oil. , Roman chamomile oil and the like (vegetable oil) are preferred. The fats and oils may be used alone or in combination of two or more.
유지분의 소독용 조성물에서의 함유 비율로는 0.5∼20중량%인 것이 바람직하고, 1.0∼10중량%인 것이 더욱 바람직하다. 그 함유 비율이 상기 범위이면 사용했을 때 사용자의 손의 거칠음 등을 방지할 수 있다.As a content ratio in the composition for disinfection of oil and fat, it is preferable that it is 0.5 to 20 weight%, and it is more preferable that it is 1.0 to 10 weight%. If the content ratio is within the above range, it is possible to prevent roughness of the user's hand when used.
본 발명에서의 증점제는 소독용 조성물의 점도를 증가시키는 성분이다. 필요에 따라 배합할 수 있다. 증점제를 사용함으로써, 소독용 조성물의 점도를 소정의 점도가 되도록 점도를 상승시킬 수 있다.The thickener in the present invention is a component that increases the viscosity of the disinfectant composition. Can be mixed as needed. By using a thickener, the viscosity of the disinfectant composition can be increased to a predetermined viscosity.
증점제로는, 예를 들면, 가교형 폴리아크릴산인 카르복시비닐폴리머나, 카르복시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스 등의 셀룰로오스 유도체, 잔탄검, 구아검, 아라비아검, 알긴산나트륨, 알긴산프로필렌글리콜, 에틸셀룰로오스, 폴리아크릴산나트륨, 시클로덱스트린 등이 바람직하고, 그 중에서도 카르복시비닐폴리머, 카르복시메틸셀룰로오스가 더욱 바람직하다. 상기 증점제는 1종만 또는 2종 이상 조합하여 사용할 수 있다.As the thickener, for example, cross-linked polyacrylic acid, carboxyvinyl polymer, carboxymethyl cellulose, hydroxyethyl cellulose, cellulose derivatives such as hydroxypropyl cellulose, xanthan gum, guar gum, gum arabic, sodium alginate, propylene alginate Glycol, ethyl cellulose, sodium polyacrylate, cyclodextrin and the like are preferred, and among these, carboxyvinyl polymer and carboxymethyl cellulose are more preferred. The thickener may be used alone or in combination of two or more.
증점제의 소독용 조성물에서의 함유 비율로는 0.1∼10중량%인 것이 바람직하고, 0.2∼7중량%인 것이 더욱 바람직하다. 그 함유 비율이 상기 범위이면 사용에 적합한 원하는 점도로 조정할 수 있다.The content of the thickener in the composition for disinfection is preferably 0.1 to 10% by weight, more preferably 0.2 to 7% by weight. If the content ratio is in the above range, it can be adjusted to a desired viscosity suitable for use.
본 발명에서의 계면활성제는 소독용 조성물을 균일하게 혼합하여 크림상의 성상을 안정시키기 위한 성분이다. 필요에 따라 배합할 수 있다. 계면활성제를 사용함으로써, 소독용 조성물의 성분인 탄소수 1∼3의 저급 알코올 등이 분리되는 것을 방지할 수 있다.The surfactant in the present invention is a component for stabilizing the creamy properties by uniformly mixing the disinfectant composition. Can be mixed as needed. By using a surfactant, it is possible to prevent separation of lower alcohol having 1 to 3 carbon atoms, which is a component of the disinfectant composition.
계면활성제로는 예를 들면, 양이온 계면활성제, 음이온계 계면활성제, 양쪽성 계면활성제, 비이온 계면활성제를 들 수 있다. 양이온 계면활성제는 수중에서 해리했을 때 양이온이 되는 계면활성제이고, 예를 들면, 알킬트리메틸암모늄염, 알킬디메틸암모늄염, 알킬벤질디메틸암모늄염 등이 바람직하다. 이 중, 알킬기는 탄소수 12∼22인 것이 바람직하고, 카운터 음이온으로서 염화물 이온, 수산화물 이온, 브롬화물 이온 등인 것이 바람직하다.Examples of the surfactant include cationic surfactants, anionic surfactants, amphoteric surfactants, and nonionic surfactants. Cationic surfactants are surfactants that become cations when dissociated in water, and are preferably, for example, alkyltrimethylammonium salts, alkyldimethylammonium salts, and alkylbenzyldimethylammonium salts. Among them, the alkyl group preferably has 12 to 22 carbon atoms, and the counter anion is preferably a chloride ion, hydroxide ion, or bromide ion.
그리고, 음이온 계면활성제는 수중에서 해리했을 때 음이온이 되는 계면활성제이고, 예를 들면, 지방산염, 모노알킬황산염, 알킬폴리옥시에틸렌황산염, 알킬벤젠설폰산염, 모노알킬인산염 등이 바람직하다. 이 중 알킬기는 탄소수 12∼22인 것이 바람직하고, 카운터 양이온으로서 나트륨 이온, 칼륨 이온, 칼슘 이온, 마그네슘 이온 등인 것이 바람직하다.The anionic surfactant is a surfactant that becomes an anion when dissociated in water. For example, fatty acid salts, monoalkyl sulfates, alkyl polyoxyethylene sulfates, alkylbenzene sulfonates, monoalkyl phosphates, and the like are preferable. Among them, the alkyl group preferably has 12 to 22 carbon atoms, and the counter cation is preferably a sodium ion, potassium ion, calcium ion, or magnesium ion.
그리고, 양쪽성 계면활성제는 분자 내에 음이온성 부위와 양이온성 부위 양방을 겸비하고 있고, 용액의 pH에 따라 양이온, 음이온 및 양이온과 음이온의 양쪽성이 되는 계면활성제이며, 예를 들면, 알킬디메틸아민옥사이드, 알킬카르복시베타인 등이 바람직하다. 이 중 알킬기는 탄소수 12∼22인 것이 바람직하다.And, the amphoteric surfactant is a surfactant that has both an anionic site and a cationic site in the molecule and becomes amphoteric between cations, anions, and cations and anions depending on the pH of the solution, for example, alkyldimethylamine. oxides, alkylcarboxybetaines and the like are preferred. Among these, the alkyl group preferably has 12 to 22 carbon atoms.
그리고, 비이온 계면활성제는 친수부가 이온화되지 않은 친수성 부위를 갖는 활성제이고, 예를 들면, 폴리옥시에틸렌세틸에테르나 폴리옥시에틸렌스테아릴에테르 등의 폴리옥시에틸렌알킬에테르, 글리세린 지방산에스테르나 소르비탄 지방산에스테르, 자당 지방산에스테르 등의 다가 알코올 지방산에스테르, 폴리옥시에틸렌 부가 다가 알코올의 지방산에스테르, 지방산디에탄올아미드 등이 바람직하다. 상기 비이온 계면활성제 중, 그리핀의 식으로부터 산출되는 HLB가 3∼17인 것이 더욱 바람직하다. 상기 비이온 계면활성제에서 폴리옥시에틸렌 골격을 갖는 것은 적절히 옥시에틸렌의 부가 몰수를 변경할 수 있다. HLB가 상기 범위의 비이온 계면활성제이면, 소독용 조성물의 보존 안정이 우수하고, 구체적으로는 시간이 경과해도 분리 등이 일어나지 않고, 크림상을 유지할 수 있다. 또한, 상기 계면활성제는 1종만 또는 2종 이상 조합하여 사용할 수 있지만, HLB 3∼6의 계면활성제와 HLB 12∼17의 계면활성제를 조합하는 것이 바람직하다.The nonionic surfactant is an active agent having a hydrophilic site in which the hydrophilic part is not ionized, and examples thereof include polyoxyethylene alkyl ethers such as polyoxyethylene cetyl ether and polyoxyethylene stearyl ether, glycerin fatty acid esters, and sorbitan fatty acids. Polyhydric alcohol fatty acid esters such as esters and sucrose fatty acid esters, fatty acid esters of polyoxyethylene-added polyhydric alcohols, fatty acid diethanolamides, and the like are preferred. Among the nonionic surfactants, those having an HLB of 3 to 17 calculated from Griffin's formula are more preferable. In the above nonionic surfactants, those having a polyoxyethylene backbone can appropriately change the number of added moles of oxyethylene. If the HLB is a nonionic surfactant within the above range, the storage stability of the composition for disinfection is excellent, and, specifically, it is possible to maintain a creamy state without separation or the like even after elapse of time. In addition, although the said surfactant can be used alone or in combination of 2 or more types, it is preferable to combine HLB 3-6 surfactant and HLB 12-17 surfactant.
또한, 본 발명의 소독용 조성물에는 물이 배합된다. 물로는 일본 약국방 규격의 물이 바람직하고, 예를 들면, 수돗물, 우물물 등인 상수, 그리고 증류, 이온 교환막에 의한 이온 교환 처리, 한외 여과막에 의한 한외 여과 처리 중 어느 것, 또는 이들의 조합에 의해 상수를 처리한 정제수, 그리고, 가열 등에 의해 정제수를 멸균 처리한 멸균 정제수 등이 바람직하다. 그리고, 상기 물의 배합 비율은 본 발명에 사용되는 에탄올, 콘드로이틴황산 또는 콘드로이틴황산염을 제외한 잔여이고, 또한, 증점제, 계면활성제 등을 배합했을 때에는 상기를 제외한 잔여이며, 40∼65중량%인 것이 바람직하고, 42∼63중량%인 것이 바람직하다.In addition, water is blended in the composition for disinfection of the present invention. As water, water of the Japanese Pharmacopoeia standard is preferable, for example, constant water such as tap water, well water, etc., and constant water by any of distillation, ion exchange treatment with an ion exchange membrane, ultrafiltration treatment with an ultrafiltration membrane, or a combination thereof. Purified water treated with, and sterilized purified water obtained by sterilizing the purified water by heating or the like are preferred. In addition, the blending ratio of the water is the remainder excluding ethanol, chondroitin sulfate or chondroitin sulfate used in the present invention, and when a thickener, surfactant, etc. are blended, it is the remainder excluding the above, preferably 40 to 65% by weight , preferably 42 to 63% by weight.
또한, 본 발명의 소독용 조성물에는 필요에 따라 소독 성분을 배합할 수 있다. 소독 성분은 탄소수 1∼3의 저급 알코올로는 충분히 소독할 수 없는 균 또는 바이러스 등도 소독하기 위해 배합된다. 소독 성분으로는 예를 들면, 벤제토늄염화물, 염화벤잘코늄, 글루콘산클로르헥시딘, 포비돈요오드, 이소프로필메틸페놀, 클로록실레놀 등이 바람직하고, 벤제토늄염화물이 더욱 바람직하다. 또한, 상기 소독 성분은 1종만 또는 2종 이상 조합하여 사용할 수 있다.In addition, a disinfectant component may be incorporated into the disinfectant composition of the present invention, if necessary. Disinfection components are formulated to disinfect germs or viruses that cannot be sufficiently disinfected with lower alcohols having 1 to 3 carbon atoms. As the disinfecting component, for example, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate, povidone iodine, isopropylmethylphenol, chloroxylenol and the like are preferable, and benzethonium chloride is more preferable. In addition, the above disinfection components may be used alone or in combination of two or more.
본 발명의 소독용 조성물에 있어서, 증점제를 배합함으로써 점도를 향상시킬 수 있기 때문에, 본 발명의 소독용 조성물의 점도는 JIS K7117-1에 기재된 브룩필드형 회전 점도계 B형(도키 산업 주식회사 제조, 상품명 「TVB-10M」)을 사용한 계측에서 25℃ 조건하 50∼300Pa·s인 것이 바람직하고, 100∼250Pa·s인 것이 보다 바람직하다. 소독용 조성물의 점도가 이 범위에 있으면, 손가락 등의 피부에 부착되어도 바로 흘러 내리지 않고, 또한 펴바를 때에도 펴바르기 쉽다.In the disinfectant composition of the present invention, since the viscosity can be improved by blending a thickener, the viscosity of the disinfectant composition of the present invention is determined by the Brookfield rotational viscometer type B described in JIS K7117-1 (manufactured by Toki Sangyo Co., Ltd., trade name In measurement using "TVB-10M"), it is preferably 50 to 300 Pa·s under 25°C conditions, and more preferably 100 to 250 Pa·s. If the viscosity of the disinfectant composition is within this range, even if it adheres to the skin of a finger or the like, it does not immediately flow down and is easy to spread even when spreading.
본 발명의 소독용 조성물에는 추가로 콘드로이틴황산 또는 콘드로이틴황산염 이외인 그 밖의 보습제를 배합할 수 있다. 그 밖의 보습제로는, 예를 들면, 글리세린, 폴리글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 1,2-펜탄디올, 1,2-헥산디올, 폴리에틸렌글리콜, 말티톨, 소르비톨 등의 다가 알코올, 히알루론산나트륨, 우레아, 락트산나트륨, 트리메틸글리신 등이 바람직하다.In the composition for disinfection of the present invention, a moisturizer other than chondroitin sulfate or chondroitin sulfate may be further incorporated. Examples of other humectants include polyhydric alcohols such as glycerin, polyglycerin, propylene glycol, 1,3-butylene glycol, 1,2-pentanediol, 1,2-hexanediol, polyethylene glycol, maltitol, and sorbitol. , sodium hyaluronate, urea, sodium lactate, trimethylglycine and the like are preferred.
본 발명의 소독용 조성물에는 상기 성분 외에 필요에 따라, 토코페롤, 비타민 C, BHT 등의 항산화제, pH 조정제, 완충제, 향료, 색소 등을 배합할 수도 있다.Antioxidants such as tocopherol, vitamin C, and BHT, pH adjusters, buffers, flavorings, pigments, and the like may be added to the disinfectant composition of the present invention, if necessary, in addition to the above components.
실시예Example
[실시예 1][Example 1]
에탄올을 30중량부, 콘드로이틴황산나트륨을 1중량부, 잔여를 물로 하여 100중량부의 조성물을 조정하고, 잘 혼합하여 소독용 조성물을 제조하였다.A composition for disinfection was prepared by mixing 30 parts by weight of ethanol, 1 part by weight of sodium chondroitin sulfate, and 100 parts by weight of the composition with the remainder water, and mixing well.
[실시예 2][Example 2]
에탄올을 50중량부로 한 것 이외에는 실시예 1과 동일하게 소독용 조성물을 제조하였다.A disinfectant composition was prepared in the same manner as in Example 1, except that 50 parts by weight of ethanol was used.
[실시예 3][Example 3]
콘드로이틴황산나트륨을 0.01중량부로 한 것 이외에는 실시예 1과 동일하게 소독용 조성물을 제조하였다.A composition for disinfection was prepared in the same manner as in Example 1, except that 0.01 part by weight of sodium chondroitin sulfate was used.
[비교예 1][Comparative Example 1]
에탄올을 10중량부로 한 것 이외에는 실시예 1과 동일하게 소독용 조성물을 제조하였다.A disinfectant composition was prepared in the same manner as in Example 1, except that ethanol was used in 10 parts by weight.
[비교예 2][Comparative Example 2]
에탄올을 70중량부로 한 것 이외에는 실시예 1과 동일하게 소독용 조성물을 제조하였다.A disinfectant composition was prepared in the same manner as in Example 1, except that ethanol was used in 70 parts by weight.
[비교예 3][Comparative Example 3]
*콘드로이틴황산나트륨을 배합하지 않은 것 이외에는 실시예 1과 동일하게 소독용 조성물을 제조하였다.* A disinfectant composition was prepared in the same manner as in Example 1, except that chondroitin sodium sulfate was not mixed.
[외관 성상][Appearance appearance]
제조 직후의 소독용 조성물의 성상에 대해 육안에 의해 평가함에 있어서, 평가 기준으로서, 콘드로이틴황산나트륨이 균일하게 용해되어 있는 상태를 「A」 평가로 하고, 콘드로이틴황산나트륨이 용해되어 있지 않거나 또는 콘드로이틴황산나트륨에 의한 흐림(cloudiness)이 발생하는 상태를 「C」 평가로 하고, 「A」평가가 바람직하며 「C」평가가 바람직하지 않은 것으로 평가하였다.In visually evaluating the properties of the disinfectant composition immediately after production, as an evaluation criterion, a state in which chondroitin sulfate is uniformly dissolved is evaluated as "A", and chondroitin sodium sulfate is not dissolved or chondroitin sodium sulfate A state in which cloudiness occurred was evaluated as "C" evaluation, "A" evaluation was evaluated as preferable, and "C" evaluation was evaluated as undesirable.
[보습성][moisturizing properties]
제조한 소독용 조성물의 보습성을 평가함에 있어서, 평가 기준으로서 전문 패널리스트 5명이 사용 후의 보습감을 1점 내지 5점의 5단계의 관능 평가를 행하고, 그 평균점을 구해, 하기의 평가 기준에 기초하여 구분하고, 「A」평가가 바람직하며 「B」평가 및 「C」평가는 바람직하지 않은 것으로 평가를 행하였다.In evaluating the moisture retention of the prepared disinfectant composition, as an evaluation standard, five professional panelists performed sensory evaluation on a five-point scale of 1 to 5 for the feeling of moisture after use, and obtained an average score based on the following evaluation criteria. and classified, and the "A" evaluation was preferable, and the "B" evaluation and the "C" evaluation were evaluated as undesirable.
A: 평균점이 4.0 이상A: An average score of 4.0 or higher
B: 평균점이 2.0 이상, 4.0 미만B: Average score of 2.0 or more and less than 4.0
C: 평균점이 2.0 미만C: average less than 2.0
*[살균 효력]*[Sterilization effect]
제조한 소독용 조성물의 살균 효력을 평가함에 있어서, 검체와 균액을 직접 접촉시킨 후 평판 배지에 도말하여, 균수의 평가를 행하였다. 평가 기준으로서, 컨트롤한 균수에 대해 상기 소독용 조성물과 접촉함으로써 사멸된 균수의 비율이 99.99% 이상의 효력인 것을 「A」평가로 하고, 99.99% 미만의 효력인 것을 「C」평가로 하고, 「A」평가가 바람직하며 「C」평가가 바람직하지 않은 것으로 평가하였다.In evaluating the bactericidal effect of the prepared disinfectant composition, the sample and the bacterial solution were directly contacted and then spread on a flat medium to evaluate the number of bacteria. As an evaluation criterion, an efficacy of 99.99% or more of the ratio of the number of bacteria killed by contact with the disinfectant composition to the controlled number of bacteria was evaluated as "A", and an efficacy of less than 99.99% was evaluated as "C", and " It was evaluated that the "A" evaluation was preferable and the "C" evaluation was undesirable.
실시예 1∼3, 비교예 1∼3에 대해, 외관 성상, 보습성, 살균 효력에 관한 결과를 표 1에 나타낸다.For Examples 1 to 3 and Comparative Examples 1 to 3, Table 1 shows the results of external appearance, moisturizing properties, and bactericidal efficacy.
표 1에 나타내는 바와 같이, 에탄올 및 물을 배합하는 조성물에 있어서, 콘드로이틴황산나트륨을 배합하면 보습성이 양호하지만, 에탄올의 배합량이 70중량부가 되면 콘드로이틴황산나트륨이 용해되지 않고, 에탄올의 배합량이 10중량부 정도인 경우에는 살균 효력이 바람직하지 않았다. 상기 결과로부터, 소독용 조성물로서, 콘드로이틴황산나트륨이 균일하게 용해되는 양호한 성상을 가지면서, 바람직한 살균 효력을 나타내기 위해서는 에탄올, 물, 및 콘드로이틴황산나트륨의 배합 비율이 소정의 범위일 필요가 있음을 알 수 있었다. As shown in Table 1, in the composition containing ethanol and water, when chondroitin sodium sulfate is incorporated, the moisturizing properties are good. In the case of the degree, the bactericidal effect was not desirable. From the above results, it can be seen that as a disinfectant composition, the mixing ratio of ethanol, water, and chondroitin sodium sulfate needs to be within a predetermined range in order to exhibit a desirable sterilization effect while having good properties in which sodium chondroitin sulfate is uniformly dissolved. there was.
[실시예 4][Example 4]
에탄올을 30중량부, 보습제인 콘드로이틴황산나트륨(1.0중량부, 증점제인 카르복시비닐폴리머(와코 순약 공업 주식회사 제조, 상품명: 「하이비스와코 103」)를 0.4중량부, 비이온 계면활성제인 폴리옥시에틸렌세틸에테르(닛코 케미컬즈 주식회사 제조, 상품명: 「NIKKOL BC-15」, HLB: 15.5)를 2중량부, 비이온 계면활성제인 모노스테아르산글리세린(닛코 케미컬즈 주식회사 제조, 상품명: 「NIKKOL MGS-AMV」, HLB: 4.0)을 2중량부, 유지분인 유동 파라핀(주오 화성 주식회사 제조, 상품명: 「유동 파라핀 350S」)을 1중량부, 유지분인 미리스트산이소프로필을 1중량부, 유지분인 스테아릴알코올을 0.5중량부, 보습제인 글리세린을 0.5중량부, 디메틸폴리실록산(도레이·다우코닝 주식회사 제조, 상품명: 「Q7-9120SILICONE FLUID350CST」)을 0.2중량부, 소독 성분인 벤제토늄염화물을 0.05중량부, 수산화나트륨을 0.072중량부, 잔여를 물로 하여 100중량부의 조성물을 조정하고, 잘 혼합하여 소독용 조성물을 제조하였다.30 parts by weight of ethanol, sodium chondroitin sulfate (1.0 part by weight) as a moisturizer, 0.4 part by weight of carboxyvinyl polymer (manufactured by Wako Pure Chemical Industries, Ltd., trade name: "Hibiswaco 103") as a thickener, polyoxyethylene cetyl as a nonionic surfactant Ether (manufactured by Nikko Chemicals, Inc., trade name: "NIKKOL BC-15", HLB: 15.5) 2 parts by weight, glycerin monostearate as a nonionic surfactant (manufactured by Nikko Chemicals, trade name: "NIKKOL MGS-AMV" , HLB: 4.0) 2 parts by weight, liquid paraffin (manufactured by Chuo Kasei Co., Ltd., trade name: "Liquid Paraffin 350S") as 1 part by weight, isopropyl myristate as oil and fat 1 part by weight, oil and fat 0.5 parts by weight of stearyl alcohol, 0.5 parts by weight of glycerin as a humectant, 0.2 parts by weight of dimethylpolysiloxane (trade name: "Q7-9120SILICONE FLUID350CST" manufactured by Toray Dow Corning Co., Ltd.), and 0.05 part by weight of benzethonium chloride as a disinfectant component , 0.072 parts by weight of sodium hydroxide, the balance was adjusted to 100 parts by weight of water, and mixed well to prepare a composition for disinfection.
[실시예 5][Example 5]
실시예 4에서 에탄올을 50중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 80Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 50 parts by weight of ethanol was used in Example 4. And as a result of measuring the viscosity similarly to Example 4, it was 80 Pa.s.
[실시예 6][Example 6]
실시예 4에서 콘드로이틴황산나트륨을 0.5중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 95Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.5 parts by weight of sodium chondroitin sulfate was used. And as a result of measuring the viscosity in the same way as in Example 4, it was 95 Pa·s.
[실시예 7][Example 7]
실시예 4에서 콘드로이틴황산나트륨을 0.1중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 101Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.1 part by weight of sodium chondroitin sulfate was used. And as a result of measuring the viscosity in the same way as in Example 4, it was 101 Pa·s.
[실시예 8][Example 8]
실시예 4에서 콘드로이틴황산나트륨을 0.01중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 95Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.01 part by weight of chondroitin sulfate was used in Example 4. And as a result of measuring the viscosity in the same way as in Example 4, it was 95 Pa·s.
[비교예 4][Comparative Example 4]
실시예 4에서 콘드로이틴황산나트륨 대신에 히알루론산나트륨을 0.01중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 128Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.01 part by weight of sodium hyaluronate was used instead of sodium chondroitin sulfate. And as a result of measuring the viscosity in the same way as in Example 4, it was 128 Pa·s.
[비교예 5][Comparative Example 5]
실시예 4에서 콘드로이틴황산나트륨을 배합하지 않고 카르복시비닐폴리머를 0.05중량부, 수산화나트륨을 0.09중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 211Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.05 parts by weight of carboxyvinyl polymer and 0.09 parts by weight of sodium hydroxide were used without mixing sodium chondroitin sulfate. And as a result of measuring the viscosity in the same way as in Example 4, it was 211 Pa·s.
[비교예 6][Comparative Example 6]
실시예 4에서 에탄올을 40중량부로 하고, 콘드로이틴황산나트륨을 배합하지 않고, 카르복시비닐폴리머를 0.05중량부, 수산화나트륨을 0.09중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 183Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4 except that 40 parts by weight of ethanol, 0.05 parts by weight of carboxyvinyl polymer, and 0.09 parts by weight of sodium hydroxide were used without mixing chondroitin sodium sulfate. And as a result of measuring the viscosity in the same way as in Example 4, it was 183 Pa·s.
[비교예 7][Comparative Example 7]
실시예 4에서 에탄올을 70중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 제조 후에 분리나 백탁 등이 있고, 실시예 4와 동일하게 점도를 측정할 수 없었다.A disinfectant composition was prepared in the same manner as in Example 4, except that ethanol was used in 70 parts by weight. And, after production, separation, cloudiness, etc. occurred, and the viscosity could not be measured similarly to Example 4.
[비교예 8][Comparative Example 8]
실시예 4에서 콘드로이틴황산나트륨을 0.005중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 105Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 0.005 parts by weight of chondroitin sulfate was used in Example 4. And as a result of measuring the viscosity in the same way as in Example 4, it was 10 5 Pa·s.
[비교예 9][Comparative Example 9]
실시예 4에서 에탄올을 10중량부로 한 것 이외에는 실시예 4와 동일하게 하여 소독용 조성물을 제조하였다. 그리고, 실시예 4와 동일하게 점도를 측정한 결과, 185Pa·s였다.A disinfectant composition was prepared in the same manner as in Example 4, except that 10 parts by weight of ethanol was used in Example 4. And as a result of measuring the viscosity in the same way as in Example 4, it was 185 Pa·s.
[외관 성상][Appearance appearance]
제조 직후의 소독용 조성물의 성상에 대해 육안에 의해 평가함에 있어서, 평가 기준으로서 콘드로이틴황산나트륨이 균일하게 용해되어 있고, 크림상이며 분리도 관찰되지 않는 상태를 「A」평가로 하고, 흐림은 있지만 콘드로이틴황산나트륨을 용해하고 있으며 분리도 관찰되지 않는 상태를 「B」, 분리되어 균일하게 되어 있지 않은 상태를 「C」평가로 하고,「A」평가 및 「B」평가가 바람직하며 「C」 평가가 바람직하지 않은 것으로 평가하였다.In visually evaluating the properties of the disinfectant composition immediately after preparation, as an evaluation criterion, a state in which sodium chondroitin sulfate is uniformly dissolved, creamy, and no separation is observed is evaluated as "A", and cloudy but chondroitin A state in which sodium sulfate is dissolved and no separation is observed is evaluated as "B", and a state in which the separation is not uniform is evaluated as "C", and "A" evaluation and "B" evaluation are preferable, and "C" evaluation is preferable. rated as not.
[보습성][moisturizing properties]
제조한 소독용 조성물의 보습성을 평가함에 있어서, 전문 패널리스트 5명이 사용 후의 보습감을 1점 내지 5점의 5단계의 관능 평가를 행하고, 그 평균점을 구하여 하기 평가 기준에 기초하여 구분하고, 「A」평가가 바람직하며 「B」평가 및 「C」평가는 바람직하지 않은 것으로 평가를 행하였다.In evaluating the moisturizing properties of the disinfectant composition prepared, 5 professional panelists performed a sensory evaluation of 5 stages of 1 to 5 for the moisturizing feeling after use, and the average score was obtained and classified based on the following evaluation criteria, " It was evaluated that "A" evaluation was preferable, and "B" evaluation and "C" evaluation were not preferable.
A: 평균점이 4.0 이상A: An average score of 4.0 or higher
B: 평균점이 2.0 이상, 4.0 미만B: Average score of 2.0 or more and less than 4.0
C: 평균점이 2.0 미만C: average less than 2.0
[살균 효력][Sterilization effect]
제조한 소독용 조성물의 살균 효력을 평가함에 있어서, 검체와 균액을 직접 접촉시킨 후 평판 배지에 도말하여 배양하고, 균수의 평가를 행하였다. 평가 기준으로서, 컨트롤한 균수에 대해 상기 소독용 조성물과 접촉함으로써 사멸된 균수의 비율이 99.99% 이상의 효력인 것을 「A」평가로 하고, 99.99% 미만의 효력인 것을 「C」평가로 하고, 「A」평가가 바람직하며 「C」평가가 바람직하지 않은 것으로 평가하였다.In evaluating the bactericidal effect of the prepared disinfectant composition, the sample and the bacterial solution were directly contacted, then smeared and cultured on a plate medium, and the number of bacteria was evaluated. As an evaluation criterion, an efficacy of 99.99% or more of the ratio of the number of bacteria killed by contact with the disinfectant composition to the controlled number of bacteria was evaluated as "A", and an efficacy of less than 99.99% was evaluated as "C", and " It was evaluated that the "A" evaluation was preferable and the "C" evaluation was undesirable.
실시예 4∼8, 비교예 4∼9에 대해, 점도, 외관 성상, 보습성, 살균 효력에 관한 결과를 표 2에 나타낸다.For Examples 4 to 8 and Comparative Examples 4 to 9, Table 2 shows the results of viscosity, appearance, moisture retention, and bactericidal effect.
표 2로부터, 에탄올, 콘드로이틴황산나트륨, 증점제, 계면활성제, 물 등의 배합계에서 에탄올, 콘드로이틴황산나트륨, 물을 소정의 함유 비율로 함으로써 소독용 조성물의 제조시에 안정적인 크림상의 성상을 유지할 수 있고, 보습성 및 살균 효력도 양호한 것을 알 수 있었다. 이와 같이 유지 성분, 증점제 및 계면활성제를 함유하고, 점도를 소정 범위로 함으로써, 탄소수 1∼3의 저급 알코올이 높은 비율로 배합되면서도 유화 안정성이 우수하고, 또한 사용할 때 손의 거칠음을 방지할 수도 있는 보습성이 양호한 반고형상의 고점도인 소독용 유화 조성물을 형성할 수 있다.From Table 2, by using ethanol, chondroitin sodium sulfate, and water in a predetermined content ratio in a formulation system such as ethanol, chondroitin sulfate, thickener, surfactant, and water, stable creamy properties can be maintained during the preparation of a disinfectant composition, and moisturizing It was found that the sterilization and bactericidal effect were also good. In this way, by containing an oil-fat component, a thickener and a surfactant, and setting the viscosity within a predetermined range, the lower alcohol having 1 to 3 carbon atoms is blended in a high ratio, the emulsion stability is excellent, and roughness of the hand can be prevented during use. A semi-solid, high-viscosity emulsion composition for disinfection with good moisture retention can be formed.
[비교예 10][Comparative Example 10]
에탄올을 78중량부, 카르복시비닐폴리머를 0.4중량부, 수산화나트륨을 0.072중량부, 잔여를 물로 하는 소독용 조성물을 제조하였다.A disinfectant composition containing 78 parts by weight of ethanol, 0.4 parts by weight of carboxyvinyl polymer, 0.072 parts by weight of sodium hydroxide, and the balance of water was prepared.
[비교예 11][Comparative Example 11]
에탄올을 54중량부, 카르복시비닐폴리머를 0.4중량부, 수산화나트륨을 0.072중량부, 잔여를 물로 하는 소독용 조성물을 제조하였다.A disinfectant composition containing 54 parts by weight of ethanol, 0.4 parts by weight of carboxyvinyl polymer, 0.072 parts by weight of sodium hydroxide, and the balance of water was prepared.
실시예 8, 비교예 10∼11의 소독용 조성물에 대해, 수분 증산량에 대해 측정하였다. 즉, 상기 소독용 조성물을 온도 약 25℃, 습도 30∼40%의 환경하에서 1회 도포 및 10회 연속 도포했을 때의 경피 수분 증산량을 1회 도포 후는 5분 및 10분 후에, 10회 연속 도포 후는 5, 10, 20, 30분 후에 Tewameter TM300(Courage+Khazaka사 제조)을 사용하여 측정하였다. 그리고, 상기 시간 경과 후의 경피 수분 증산량과, 도포 전의 경피 수분 증산량의 차로부터 변화량을 산출하고, 피부의 피부 배리어성을 평가하였다. 1회 도포 및 10회 연속 도포했을 때로부터 10분 후 이후에서의 경피 수분 증산량으로부터, 도포 전의 경피 수분 증산량을 뺀 차인 변화량을 산출하고, 이 변화량이 마이너스인 것을 양호한 것으로 평가하였다. 상기 결과를 표 3에 나타낸다.About the composition for disinfection of Example 8 and Comparative Examples 10-11, the amount of water evaporation was measured. That is, the amount of transdermal water evaporation when the disinfectant composition was applied once and 10 consecutive times in an environment of a temperature of about 25° C. and a humidity of 30 to 40% was measured 5 minutes and 10 minutes after application once, 10 times in a row. 5, 10, 20, and 30 minutes after application were measured using a Tewameter TM300 (manufactured by Courage + Khazaka). Then, the amount of change was calculated from the difference between the amount of transepidermal water evaporation after the lapse of time and the amount of transepidermal water evaporation before application, and the skin barrier properties of the skin were evaluated. The amount of change, which is the difference between the amount of transepidermal water evaporated before application and the amount of transepidermal water evaporated 10 minutes after 10 minutes after the first application and 10 consecutive applications, was calculated, and a negative change was evaluated as good. The results are shown in Table 3.
표 3으로부터, 실시예 8에서의 소독용 조성물에서는 1회 도포 후 및 10회 도포 후에서, 10분 후 이후의 경피 수분 증산량이 도포 전의 경피 수분 증산량보다 작고, 10분 후 이후에서의 경피 수분 증산량의 초기의 경피 수분 증산량으로부터의 변화량이 마이너스의 수가 되고, 수분의 증산이 억제되어 피부 배리어성에 대해, 비교예 10∼11에 비해 우수함을 알 수 있었다. 또한, 피부 배리어성이 우수함으로써, 피부로부터의 세균이나 바이러스의 침입 및 감염을 예방할 수 있다. From Table 3, in the disinfectant composition in Example 8, after 1 application and after 10 applications, the amount of transdermal water loss after 10 minutes is smaller than the amount of transepidermal water loss before application, and the amount of transdermal water loss after 10 minutes It was found that the amount of change from the initial transdermal water evaporation amount was a negative number, and water evaporation was suppressed, and the skin barrier properties were superior to those of Comparative Examples 10 to 11. In addition, by having excellent skin barrier properties, invasion and infection of bacteria or viruses from the skin can be prevented.
Claims (1)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017055369A JP6830629B2 (en) | 2017-03-22 | 2017-03-22 | Disinfectant composition |
JPJP-P-2017-055369 | 2017-03-22 | ||
PCT/JP2018/010226 WO2018173917A1 (en) | 2017-03-22 | 2018-03-15 | Disinfectant composition |
KR1020197030005A KR20190126135A (en) | 2017-03-22 | 2018-03-15 | Disinfection Composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197030005A Division KR20190126135A (en) | 2017-03-22 | 2018-03-15 | Disinfection Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230086819A true KR20230086819A (en) | 2023-06-15 |
Family
ID=63584392
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020237019184A KR20230086819A (en) | 2017-03-22 | 2018-03-15 | Composition for disinfection |
KR1020197030005A KR20190126135A (en) | 2017-03-22 | 2018-03-15 | Disinfection Composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197030005A KR20190126135A (en) | 2017-03-22 | 2018-03-15 | Disinfection Composition |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6830629B2 (en) |
KR (2) | KR20230086819A (en) |
CN (1) | CN110545825A (en) |
TW (1) | TWI771388B (en) |
WO (1) | WO2018173917A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102229814B1 (en) | 2020-07-24 | 2021-03-19 | (주)뉴젠사이언스 | Cleaning wipes for sterilization and disinfection and the manufacturing method thereof |
KR102202917B1 (en) | 2020-07-24 | 2021-01-14 | (주)뉴젠사이언스 | Compositions for sterilization and disinfection and the manufacturing method thereof |
KR102229800B1 (en) | 2020-07-24 | 2021-03-19 | (주)뉴젠사이언스 | Compositions for sterilization and disinfection comprising enzyme and the manufacturing method thereof |
KR102345209B1 (en) * | 2021-09-08 | 2022-01-03 | 김인희 | Sanitizer composition has excellent anti-viral effect, sterilization effect and skin moisturizing effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10130173A (en) | 1996-10-28 | 1998-05-19 | Japan Medic Kk | Quick-drying disinfectant |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06128125A (en) * | 1992-10-14 | 1994-05-10 | Kose Corp | Hair tonic |
JPH09110680A (en) * | 1995-10-19 | 1997-04-28 | Yuutoku Yakuhin Kogyo Kk | Dermatitis-curing strap |
JPH10324624A (en) * | 1997-05-23 | 1998-12-08 | Kao Corp | Bactericidal disinfectant composition |
-
2017
- 2017-03-22 JP JP2017055369A patent/JP6830629B2/en active Active
-
2018
- 2018-03-13 TW TW107108380A patent/TWI771388B/en active
- 2018-03-15 KR KR1020237019184A patent/KR20230086819A/en not_active Application Discontinuation
- 2018-03-15 KR KR1020197030005A patent/KR20190126135A/en active Application Filing
- 2018-03-15 WO PCT/JP2018/010226 patent/WO2018173917A1/en active Application Filing
- 2018-03-15 CN CN201880019987.8A patent/CN110545825A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10130173A (en) | 1996-10-28 | 1998-05-19 | Japan Medic Kk | Quick-drying disinfectant |
Also Published As
Publication number | Publication date |
---|---|
TW201836619A (en) | 2018-10-16 |
JP6830629B2 (en) | 2021-02-17 |
KR20190126135A (en) | 2019-11-08 |
TWI771388B (en) | 2022-07-21 |
WO2018173917A1 (en) | 2018-09-27 |
JP2018158890A (en) | 2018-10-11 |
CN110545825A (en) | 2019-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5925758B2 (en) | Antibacterial composition | |
KR20230086819A (en) | Composition for disinfection | |
ES2607055T3 (en) | Antimicrobial compositions | |
KR20070113281A (en) | Antimicrobial compositions and methods | |
PL194676B1 (en) | Composition having antimicrobial properties and method of disinfecting surfaces | |
BRPI0414220B1 (en) | antimicrobial composition | |
US20090082472A1 (en) | Hand sanitizer and method of preparation | |
JPWO2007094332A1 (en) | Disinfecting ointment | |
KR102338256B1 (en) | Hand sanitizer composition that contains ionized calcium and has excellent skin moisturizing effect, sterilization effect and viral effect | |
WO2015146398A1 (en) | Deodorant composition and deodorant agent | |
KR20170036058A (en) | Cineole-containing composition for nasal application | |
JP2011074082A (en) | Antiseptic sterilizer and composition for application to human body | |
JP2021046382A (en) | Antiperspirant composition | |
JP2007284412A (en) | Germicidal disinfectant cream | |
KR102345209B1 (en) | Sanitizer composition has excellent anti-viral effect, sterilization effect and skin moisturizing effect | |
JP2007217394A (en) | Pharmaceutical composition | |
JP6741433B2 (en) | Emulsion composition for disinfection | |
JP4734293B2 (en) | Antiseptic disinfectant and human body composition | |
KR20120053874A (en) | Thickener, emulsifying stabilizer and composition for skin external application containing natural polymer | |
KR101536043B1 (en) | Aqueous composition to be contained in container | |
JP5507146B2 (en) | Water-in-oil emulsified paste pharmaceutical preparation for lips | |
KR20190042164A (en) | Composition and method for non-atiseptic wet tissues containing the ingredient to inhibit microbial propagation | |
JP7045750B1 (en) | Alcohol-based rubbing-type hand disinfection composition with improved usability | |
WO2023276203A1 (en) | Better-feeling alcohol-based rub-in hand sanitizer composition | |
KR101461666B1 (en) | An o/w type emulsification drug containing prednisolone valerate acetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal |